BDMDHealthcare · Medical DevicesBDMD Stock Forecast: Baird Medical Investment Holdings Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 1 Aug 2026 — in the weakest quartile.
BDMD stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Baird Medical Investment Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (83): Smaller than most of the companies we track.
Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Baird Medical Investment Holdings Ltd. — and when they’d sell — is the membership.
BDMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BDMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BDMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Baird Medical Investment Holdings Ltd. (BDMD) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 3.2×
- Price / sales
- 1.5×
- Price / book
- 0.7×
- EV / EBITDA
- −2.1×
Cheaper than 68% of US stocks
Cheaper than 60% of US stocks
Cheaper than 80% of US stocks
Cheaper than 72% of US stocks
- Revenue growth (YoY)
- −39.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −104.1%
- Net margin
- −121.0%
Higher than 7% of US stocks
Higher than 14% of US stocks
Higher than 5% of US stocks
- Return on equity
- −77.6%
- Return on assets
- −21.7%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BDMD vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BDMD appears on the weeks it earns a place.
Frequently asked questions about BDMD stock
How does Ticker Nerd's model rank BDMD?
As at 1 Aug 2026, Baird Medical Investment Holdings Ltd. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).
What is the BDMD stock forecast for 2030?
No analyst covering Baird Medical Investment Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDMD are extrapolating price history, which says nothing about the business.
How has BDMD stock performed over the past year?
Baird Medical Investment Holdings Ltd. returned -44.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Baird Medical Investment Holdings Ltd. do?
Baird Medical Investment Holdings Limited is a medical devices company specializing in microwave ablation technology for minimally invasive tumor treatment. The company develops and manufactures microwave ablation apparatus, needles, and related medical devices used to treat benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, breast lumps, and bone lesions.
About Baird Medical Investment Holdings Ltd.
Baird Medical Investment Holdings Limited is a medical devices company specializing in microwave ablation technology for minimally invasive tumor treatment. The company develops and manufactures microwave ablation apparatus, needles, and related medical devices used to treat benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, breast lumps, and bone lesions. Operating primarily in the People's Republic of China, Baird Medical positions its microwave ablation systems as safer alternatives to traditional surgical approaches, offering patients faster recovery times and lower complication rates. The company's products are FDA 510(k)-certified and have been deployed across hospitals and clinics internationally. Baird Medical distributes its microwave ablation devices and consumables through third-party distributors and maintains a focus on expanding its presence in minimally invasive medical interventions. The company also pursues research and development initiatives in surgical robotics and intelligent diagnostic systems to complement its core medical device business.
CEO Ms. Haimei Wu · 146 employees · China · https://bairdmed.com